Top

News & Events

Archive: 2019

News Archive

BIA BioProcessUK Conference 2019

26 - 28 November 2019
BIA BioProcessUK Conference 2019
​Location tbc

Read more »

Lifestars Awards 2019

19 November 2019
Lifestars Awards 2019
London, UK

Read more »

UK Bioscience Forum 2019

17 October 2019
UK Bioscience Forum 2019
London, UK

Read more »

OBN Awards 2019

07 November 2019
OBN Awards 2019
Oxford, UK

Read more »

OBN BioForward 2019

11 October 2019
OBN BioForward 2019
Birmingham, UK

Read more »

One Nucleus - On Career Track

07 October 2019
One Nucleus - On Career Track
Instinctif Partners Office 

Read more »

OBN BioTuesday: 'What's New in Antimicrobial Resistance - Is There Light at the End of the Tunnel?'

16 July 2019
OBN BioTuesday: 'What's New in Antimicrobial Resistance - Is There Light at the End of the Tunnel?'
Manchester, UK

Read more »

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Ingelheim am Rhein, Germany and Geneva, Switzerland – Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform.

Read more »

Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California

SYDNEY Australia – Australian immuno-oncology company Imugene Ltd (ASX:IMU), today announced it would acquire Vaxinia Pty Ltd and separately acquire a worldwide exclusive license to a promising oncolytic virus technology, known as CF33, developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California.

Read more »

HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers

New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial of HB-201, a TheraT®*-based immunotherapy, for the treatment of Human Papilloma Virus (HPV)-positive cancers is now effective following the clearance by the U.S. Food and Drug Administration (FDA).

Read more »

BIA Summer Networking Reception 2019

11 July 2019
BIA Summer Networking Reception
London, UK

Read more »

Prescient Therapeutics Initiates Phase 1b Clinical Trial for First-in Class Anti-Cancer Drug PTX-100 in Patients with Multiple Cancers

MELBOURNE Australia – Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, today announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.

Read more »

Dr Neil Thompson Appointed Chief Scientific Officer of Healx to Spearhead Drug Discovery Expansion

Cambridge, UK – Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).

Read more »

Outcome of strategic review and trading update

Cambridge, UK - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces the outcome of its strategic review following the appointment of Dr Tom Oakley as CEO in April 2019. The Board is also pleased to provide a trading update on the year ended 31 May 2019.

Read more »

On Helix 2019

9-10 July 2019
On Helix 
Cambridge, UK

Read more »

Recce Board Changes - Appointment of Independent Chair and Additional Director

SYDNEY, Australia - Recce Pharmaceuticals Ltd (ASX: RCE, “Recce” or the “Company”), the company developing a new class of synthetic antibiotics, today announced that Dr John Prendergast has been appointed to Independent Chair with founder Dr Graham Melrose stepping back from the role of Executive Chair to Executive Director and Chief Research Officer. In addition, the Company’s Principle Chemist, Dr Justin Ward, has been appointed to the Board as Executive Director. These changes are effective today.

Read more »

Imugene: New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.

Read more »

Immatics Appoints Harpreet Singh as Chief Executive Officer

Tuebingen, Germany and Houston, Texas – Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).

Read more »

Seventure Partners Announces First Close of New Fund, Sport & Performance Capital

Paris, France Seventure Partners, one of Europe’s leaders in financing innovation in Life sciences and associated industries, announces the launch of Sport & Performance Capital™, a new fund dedicated to supporting innovation in the sport and wellness industries. With a final target of €80 million, the venture fund will invest in startup companies and growing SMEs furthering physical activity to help promote health and physical fitness.

Read more »

Instinctif Partners Supports ON Helix 2019 as Media Partner

04 July 2019, London: Instinctif Partners, the business communications consultancy, and a Silver Member of One Nucleus, is pleased to extend its relationship with One Nucleus by supporting ON Helix 2019, as Media Partner.

Read more »

Business Update and Board Changes

Manchester, UK – 4 July 2019 - SkinBioTherapeutics plc (AIM: SBTX or the “Company”), a life sciences company focused on skin health, announces changes to its Board and executive team and provides a business update.

Read more »

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Ghent, Belgium, and Dresden, Germany - Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR).

Read more »

Seventure Partners Life Sciences Corporate Update Health for Life: March 2019 – June 2019

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, is pleased to provide an update on its Health for Life investments for the period March 2019 to June 2019 (Note: June 27 is now marked The World Microbiome Day).

Read more »

RevoluGen announces a global distribution agreement for its combined High Molecular Weight DNA (HMW-DNA) extraction and size selection product Fire Monkey / Fire Flower with Merck

Hadfield, UK – RevoluGen Limited announced today a global distribution agreement for its Fire Monkey / Fire Flower product with Merck. The Fire Monkey / Fire Flower product is a kit that can be used to perform either the Fire Monkey purification of DNA for long-read sequencing applications, utilizing its reliable, rapid, user friendly protocol, or to perform the Fire Flower DNA size selection protocol.

Read more »

One Nucleus - Scaling-up Success in Biotech

27 June 2019
One Nucleus - Scaling-up Success in Biotech
Cambridge, UK

Read more »

Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.

Read more »

RevoluGen Appoints Stefano Giolito as Chief Marketing Officer

Ascot, UK – RevoluGen, a privately held scientific company specialising in the development and commercialisation of nucleic acid isolation and purification products, today announces the appointment of Stefano Giolito as Chief Marketing Officer, effective immediately.

Read more »

Clinigen - MHRA licenses two Melatonin products indicated for short-term jet-lag treatment in adults

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has been granted marketing authorisations for Melatonin 1mg/ml Oral Solution and Melatonin 3mg Film-Coated Tablets by the Medicines and Healthcare products Regulatory Agency (MHRA). Both forms are indicated for the short-term treatment of jet-lag in adults.

Read more »

Clinigen broadens partnership with Accord Healthcare to supply and distribute Cardioxane® and Savene® in Poland

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Commercial Medicines business has signed an exclusive agreement with Accord Healthcare (‘Accord’) to supply and distribute Clinigen’s speciality medicines, Cardioxane® and Savene® in Poland.

Read more »

BIA UK CEO and Investor Forum 2019

24-25 June 2019
BIA UK CEO and Investor Forum 2019
Chesham, UK

Read more »

Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication.

Read more »

Microbiotica Presenting at Key Industry Events during Summer 2019

Cambridge, UK - Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference attendance and during summer 2019. CEO Dr Mike Romanos, CSO Dr Trevor Lawley and Head of Bioinformatics Dr Simon Harris will be presenting on commercial and scientific advances and opportunities in the fast-moving microbiome space.

Read more »

Instinctif Partners congratulates Sam Fazeli on winning “Media Commentator of the Year” at the European Mediscience Awards 2019

14 June 2019, London: Instinctif Partners, the business communications consultancy, is delighted to congratulate Sam Fazeli, Head of EMEA Research at Bloomberg Intelligence, for winning the “Media Commentator of the Year” award at the European Mediscience Awards last night, in recognition of his outstanding contribution to the Life Science sector.

Read more »

European Mediscience Awards 2019

13 June 2019
European Mediscience Awards 2019
London, UK

Read more »

British Company Behind Groundbreaking Breast Cancer Treatment

Cambridge, UK - A new set of statistically significant overall survival (OS) data unveiled at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract# LBA1008), and published in The New England Journal of Medicine, are being heralded as a major breakthrough for pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer premenopausal women with advanced breast cancer.

Read more »

Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)

Pleasanton, CA and Tokyo, Japan - Astex Pharmaceuticals, Inc. a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and decitabine fixed-dose combination (ASTX727) vs decitabine IV in adults with intermediate and high-risk MDS or CMML.

Read more »

The Future of Life Science Communications

Sue Charles, Managing Partner of Instinctif Partners’ Healthcare and Life Sciences Practice, was interviewed for a video commissioned by One Nucleus. Here are her insights:

Read more »

Updated Phase Ib HER-Vaxx data presented at the American Society of Clinical Oncology 2019 Annual Meeting

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine was presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019.

Read more »

Instinctif Partners Makes Managing Partner Promotions

Instinctif Partners’ Corporate and Capital Markets practice has made two Managing Partner promotions in its UK business.

Read more »

National Care Group expands into Wales for the first time with the acquisition of the Integra Group

Accrington, UK – National Care Group (“NCG”), a leading provider of support services, announces the acquisition of the business and assets of the Integra Group (“Integra”). Financial details of the deal were not disclosed.

Read more »

Bio International Convention 2019

3-6 June 2019
Bio International Convention
Philadelphia, USA

Read more »

Leading Physician to Chair Clinical Advisory Committee

SYDNEY, Australia – Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of synthetic antibiotics, today announced the formation of a Clinical Advisory Committee to assist in the Board’s growing clinical considerations under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).

Read more »

Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the second milestone has successfully been achieved under Autifony’s agreement with Boehringer Ingelheim. This comes less than four months after achievement of the first milestone, and shortly after the company announced positive clinical data from its ketamine challenge study. Boehringer Ingelheim acquired an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform in December 2017. Further details of the milestone were not disclosed.

Read more »

First Czech Republic Diabetic Patient with Critical Limb Ischaemia Treated with Novel Regenerative Therapy by Associate Professor Václav Procházka at University Hospital Ostrava

London, UK – The first diabetic patient in the Czech Republic with a potentially life-threatening cardiovascular disease, called critical limb ischaemia (CLI), has been treated with REX-001, a novel regenerative therapy, in the SALAMANDER clinical trial being undertaken by Associate Professor Václav Procházka, the Principal Investigator at University Hospital Ostrava and an international expert in CLI.

Read more »

ADC Therapeutics Expands to Third Program Using Synaffix’s ADC Platform under Existing Agreement

AMSTERDAM, NETHERLANDS – Synaffix B.V., a Dutch biotechnology company focused on the advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that ADC Therapeutics has triggered a third target-specific license under its existing Commercial License Agreement dated October 2016.

Read more »

HKEX Biotech Week 2019

28-29 May 2019
HKEX Biotech Week 2019
Hong Kong, China

Read more »

Rexgenero Successfully Expands Manufacturing of REX-001 through Partnership with German Red Cross Blood Donor Service

London, UK – Rexgenero, a regenerative medicine company developing advanced cell-based therapies to treat critical limb ischaemia (CLI), today announces that it has successfully expanded manufacturing of its lead development candidate REX-001 through a partnership with the German Red Cross Blood Donor Service in Frankfurt, Germany, signed earlier this year.

Read more »

Bio Integrates 2019

22 May 2019
Bio Integrates 2019
London, UK

Read more »

Morphoseq™ Novel DNA Sequencing Technology Enables Highly Accurate and Cost Effective Long Read Sequencing on Short Read NGS Platforms

Sydney, Australia – Longas Technologies Pty Ltd (‘Longas’), a developer of Next Generation Sequencing (NGS) technologies, has provided details on its Morphoseq™ library prep and associated software technology at the ‘Sequencing, Finishing and Analysis in the Future’ meeting, May 21 – 23, Santa Fe, NM, USA, that enables long read sequencing on short read NGS platforms.

Read more »

HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent Business Highlights

New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reported recent business highlights and financial results for the first quarter ended March 31, 2019.

Read more »

Bio€quity Europe 2019

20-21 May 2019
Bio€quity Europe 2019
Barcelona, Spain

Read more »

Ernst & Young IPO Retreat 2019

20-21 May 2019
Ernst & Young IPO Retreat 2019
Surrey, UK 

Read more »

Global Biotechnology and Venture Capital Executive Joins Imugene Board

SYDNEY, Australia – The Board of Imugene Limited today announced the appointment of leading biotechnology executive and entrepreneur Dr Jens Eckstein as a Non-Executive Director, effective 20 May 2019.

Read more »

Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors

Maastricht, The Netherlands – Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced three upcoming poster presentations that highlight CPC634 positive data from its three phase 1 safety and biodistribution studies at the ASCO 2019 meeting, Chicago, Illinois May 31st - June 4th.

Read more »

Talis Capital Digital Health Summit

16 May 2019
Talis Capital Digital Health Summit
London, UK

Read more »

Longas Launches, Unveiling Morphoseq™ Long Read DNA Sequencing Technology

Sydney, Australia  – Longas Technologies Pty Ltd (‘Longas’), a developer of Next Generation Sequencing (NGS) technologies, today emerges from stealth mode, unveiling its Morphoseq™ technology and announcing the appointment to CEO of Nick McCooke, who built and led the team at Solexa that pioneered NGS prior to the company being acquired by Illumina.

Read more »

14th Annual World Advanced Therapies & Regenerative Medicine Congress

15 - 17 May 2019
14th Annual World Advanced Therapies & Regenerative Medicine Congress
London, UK

Read more »

Civica Rx and Xellia Pharmaceuticals join forces to reduce chronic drug shortages

Lehi, UT and Buffalo Grove, IL - Civica Rx (Civica, Inc.) and Xellia Pharmaceuticals today announced they have signed a product supply agreement under which Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s member health systems. Shortages of these anti-infective medications are impacting patient care in hospitals across the United States

Read more »

New tissue clearing kits and reagents for faster, accurate 3D imaging

Cambridge, UK – Abcam’s tissue clearing kits and reagents enable easy and rapid clearing for 3D imaging of tissues and cell culture models.

Read more »

Instinctif Partners Congratulates the Shortlisted Nominees for the European Mediscience Awards 2019

London: Instinctif Partners, the business communications consultancy, congratulates all of the nominees shortlisted as finalists for the European Mediscience Awards 2019, especially those individuals and companies in the category, Mediscience Commentator of the Year, of which Instinctif Partners is the sponsor, for the 11th year.

Read more »

HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead

New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”) for development of a therapeutic hepatitis B virus (HBV) vaccine. Based on the terms of the agreement, HOOKIPA is entitled to a milestone payment from Gilead.

Read more »

Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting

IRVINE, Calif. and BASEL, Switzerland – Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has announced that Dr. David Staskin presented positive, Phase 3 pivotal data demonstrating safety and efficacy of vibegron during a plenary session at the 2019 American Urological Association Annual Meeting (AUA) in Chicago on Sunday 5th May. Vibegron is an investigational novel, once-daily oral beta-3 adrenergic agonist being evaluated as a treatment for adults with symptoms of overactive bladder (OAB). Dr. Staskin, a leading urologist with St. Elizabeth’s Medical Center, and an Associate Professor of Urology at Tufts University School of Medicine in Boston, is a key investigator for vibegron.

Read more »

Confo Therapeutics raises €30 million in Series A financing

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The investment was led by BioGeneration Ventures (BGV) and co-led by Wellington Partners, with the addition of new investors Fund+ and Perceptive Advisors. Existing investors Capricorn Health-Tech Fund, Qbic, Participatie Maatschappij Vlaanderen NV (PMV), MINTS (University of Michigan), V-Bio Ventures and VIB also took part in the current financing round.

Read more »

Engitix Ltd Appoints Gino Van Heeke as Chief Scientific Officer

London, UK – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces the appointment of Gino Van Heeke, PhD, as Chief Scientific Officer (CSO), effective 7th May.

Read more »

WISE enrols first patient in pivotal clinical study of novel neuro-electrodes for brain monitoring

Milan, Italy - WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring and neuromodulation, has enrolled its first patient in the pivotal clinical study of its WISE Cortical Strip.

Read more »

AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091

Geneva, Switzerland - AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128, with Boehringer Ingelheim’s anti-PD1 compound, BI754091, in Microsatellite Stable (MSS) patients with stage IV colorectal cancer.

Read more »

Clinigen appoints James Meyer as General Manager of Commercial Medicines in the US

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed James (‘Jim’) Meyer as General Manager, Commercial Medicines, US, with immediate effect.

Read more »

Omnipotence cannot be next to godliness

There comes a time in any company’s life, when those in charge realise they cannot do or know everything, i.e. they are not omnipotent and therefore, they must seek external advice.

Read more »

Cell Medica collaborators, Baylor College of Medicine and Texas Children’s Hospital, present preclinical data for an off-the-shelf CAR-NKT therapy platform at American Society of Gene & Cell Therapy 22nd Annual Meeting

HOUSTON and LONDON – Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, today announced that collaborators from Baylor College of Medicine and Texas Children’s Hospital presented the latest preclinical data generated as part of the development program for CMD-502, an off-the-shelf CAR-NKT therapy candidate for R/R CD19 expressing B-cell malignancies, at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C.1

Read more »

Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors

CAMBRIDGE, UK – Mission Therapeutics (“Mission”), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the appointment of Dr. James Summers as an independent member to its Board of Directors, with immediate effect.

Read more »

OBN BioTrinity 2019

30 April - 1 May 2019
OBN BioTrinity 2019
London, UK

Read more »

Cell Medica collaborators, Baylor College of Medicine and Texas Children’s Hospital, present positive early patient data from CAR-NKT neuroblastoma trial at American Society of Gene & Cell Therapy 22nd Annual Meeting

HOUSTON and LONDON – Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, today announced that its collaborators from Baylor College of Medicine and Texas Children’s Hospital presented the latest positive progress in the GINAKIT2 trial for children with R/R high risk neuroblastoma at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C.*

Read more »

Biotec Pharmacon Q1 2019 Results

Tromsø, Norway - Biotec Pharmacon (OSE: Biotec) announces its Q1 2019 results to 31 March 2019.

Read more »

Congenica Raises Additional £13.25M ($17.1M) to Reach Total of £23.3M ($30.1M) for Series B Funding Round

Cambridge, United Kingdom – Congenica, the global clinical decision support platform provider, today announced it has raised a further £13.25 ($17.1) million in additional equity investment, led by Parkwalk Advisors. The round attracted new strategic investors, including Digital China Health Technologies Corporation Limited (DCHealth), alongside follow-on funding from existing investors. The total amount raised across its B round financings is now £23.3 ($30.1) million.

Read more »

ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer

Basel, Switzerland - ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the round and were joined by BPI France, Schroder Adveq and the German High-Tech Gründerfonds (HTGF).

Read more »

National Care Group appoints James Allen as Chief Executive Officer

Accrington, UK – National Care Group (“NCG”), a leading provider of support services, is delighted to announce the appointment of James Allen as Chief Executive Officer.

Read more »

HOOKIPA Appoints David R. Kaufman to its Board of Directors

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of David R. Kaufman, M.D., Ph.D., to its Board of Directors.

Read more »

Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia

London, UK – Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat critical limb ischaemia (CLI), today presented an update on its two Phase III SALAMANDER trials being conducted across Europe for its lead development programme REX-001 to treat CLI in patients with diabetes.

Read more »

Cell & Gene Meeting on the Mediterranean

23 - 25 April 2019
Cell & Gene Meeting on the Mediterranean
Barcelona, Spain

Read more »

Congenica Co-founder and Scientific Director Dr Matthew Hurles Elected to Fellowship of the Royal Society

Cambridge, United Kingdom – Congenica, the global diagnostic decision support platform provider, congratulates its co-founder and Scientific Director, Dr Matthew Hurles, FMedSci FRS, who has been elected to Fellowship of the Royal Society, the UK’s most prestigious scientific organisation.

Read more »

HOOKIPA Pharma Announces Pricing of Initial Public Offering

New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $14.00 per share. In addition, HOOKIPA has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $84 million, excluding any exercise of the underwriters’ option to purchase additional shares.

Read more »

SkinBioTherapeutics plc: Director Appointment

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX or the “Company”), a life sciences company focused on skin health, announces the appointment of Stuart John Ashman to the Board as a Director with effect from 18 April 2019. As previously stated in the Company’s announcement dated 29 March 2019, the intention is for Mr Ashman to succeed Dr Cath O'Neill as Chief Executive Officer following a period of transition, which will enable him to gain an understanding of the business and allow for an orderly handover. This will also enable Dr O'Neill to focus on the scientific development of the Company and the ongoing commercial discussions she has initiated.

Read more »

Cell Medica collaborator, Baylor College of Medicine, showcasing promise of CAR-NKT therapies at American Society of Gene & Cell Therapy 22nd Annual Meeting

HOUSTON and LONDON – Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, announced today that its collaborators from Baylor College of Medicine and Texas Children’s Hospital will be presenting the latest progress related to its innovative CAR therapy utilizing natural killer T cells (CAR-NKT) at the upcoming 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) April 29 – May 2 in Washington, D.C.

Read more »

Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval

Cambridge, UK - Astex Pharmaceuticals (Astex), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen). This follows the United States Food and Drug Administration’s (FDA) accelerated review and approval of a Janssen New Drug Application (NDA) for BALVERSA™ (erdafitinib) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) which has susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Read more »

BIA Regional Breakfast - London

11 April 2019
BIA Regional Breakfast
London, UK

 

Read more »

Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator

Stevenage, UK and Orlando, Fla., US – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced the positive results of AUT00206 in a Phase Ib “ketamine challenge” study in healthy volunteers.  AUT00206 demonstrated a significant central nervous system effect, consistent with modulation of Kv3.1/Kv3.2 ion channels, which is a first for this mechanism of action in human subjects.

Read more »

Synaffix Announces License Agreement worth up to $125 million with Leading Chinese ADC Developer, Shanghai Miracogen

AMSTERDAM, NETHERLANDS – Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered into a license agreement with Shanghai Miracogen Inc., a Chinese biotechnology company with a clinical-stage pipeline of ADCs.

Read more »

Polyganics Builds New Facility to Continue Growth, Supported by RIG Subsidy of €3.8 Million

Groningen, The Netherlands – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, is expanding its capacity with a new facility at the Zernike Campus, Groningen, to enter a new phase of commercial and R&D growth. Polyganics has been awarded a subsidy of €3.8 million by the Regional Investment Aid Groningen (RIG) initiative to support this development.

Read more »

Rexgenero To Present at Upcoming Investor and Cell & Gene Therapy Conferences

London, UK – Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat critical limb ischaemia (CLI), announces today that it will present at upcoming investor and cell therapy conferences over the coming month.

Read more »

Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers

Houston, Texas –  Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA203, its third T-cell receptor (TCR)-transduced adoptive cell therapy program. IMA203 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach and is based on genetic engineering of the patient’s own T cells to express an exogenous TCR. The goal is to redirect and activate the T cells to treat solid tumors.

Read more »

CEO of Feedback Medical appointed CEO of Feedback plc

Cambridge, UK - Feedback plc (AIM: FDBK, "Feedback", or the “Company”), the specialist medical imaging technology company, has appointed Dr Tom Oakley as its Chief Executive Officer with immediate effect. This follows his appointment as CEO of its operating subsidiary, Feedback Medical Ltd on 14 February 2019. Dr Alastair Riddell will resume the role of Non-Executive Chairman of Feedback, the position he held prior to becoming Executive Chairman in July 2018.

Read more »

SkinBiotix® shows efficacy in first human study

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”), a life science company focused on skin health, provides the results of its first human study.

Read more »

J.P. Morgan Healthcare Conference: The Mood Music Insight

With political uncertainty looming over both sides of the Atlantic, the future of the healthcare industry is more blurry than bright.

Read more »

Theodora Harold to be appointed new CEO at Crescendo Biologics

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Theodora Harold, the current CFO, will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019. 

Read more »

Medical University Vienna presents positive new data on one of Imugene’s lead PD-1 mimotope cancer vaccines at the American Association for Cancer Research 2019 Annual Meeting

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, together with the Medical University Vienna today presented positive new data on the PD-1 mimotope cancer vaccine program at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Read more »

AgomAb Therapeutics Completes Euros 21m Series A Financing

Ghent, Belgium – AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured EUR 21m in a Series A financing round from a strong international investor syndicate. It also announces the exercise of an exclusive license agreement with argenx SE (Euronext & Nasdaq: ARGX, ‘argenx’) and a number of senior appointments to its Leadership Team and Board of Directors.

Read more »

EspeRare enters into partnership with Dermelix Biotherapeutics to develop DMX-101, an in utero treatment for X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

Geneva, Switzerland – EspeRare, a not-for-profit organization dedicated to accelerating the development of rare diseases treatments, today announced that it has entered into an agreement with Dermelix Biotherapeutics for the co-development of its lead programme, DMX-101. DMX-101 is a novel in utero protein replacement therapy for the treatment of X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare pediatric genetic disease.

Read more »

Biotec Pharmacon’s subsidiary, ArcticZymes, granted €254k funding from Eurostars for a synthetic biology project

Tromsø, Norway – Biotec Pharmacon (OSE: Biotec) announced today that its subsidiary, ArcticZymes, has been granted €254k as part of a collaborative project on the development of novel enzymes for synthetic biology.

Read more »

Instinctif Partners sponsors “Media Commentator of the Year” at the European Mediscience Awards 2019

London, UK: Instinctif Partners, the business communications consultancy, announces that it is sponsoring the “Media Commentator of the Year” category again at the European Mediscience Awards 2019. This marks the 11th consecutive year that Instinctif Partners has been a sponsor at the awards.

Read more »

Clinigen completes acquisition of US rights to Proleukin

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has completed the acquisition of the US rights to Proleukin® (aldesleukin, human recombinant interleukin-2), following US anti-trust clearance.

Read more »

New Data on Imugene’s Lead PD-1 KEY-Vaxx and HER-2 B-Vaxx Cancer Vaccines presented at the American Association for Cancer Research 2019 Annual Meeting

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Read more »

Positive New Data on Imugene’s HER-Vaxx Cancer Vaccine Phase Ib trial presented at the American Association for Cancer Research 2019 Annual Meeting

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today presented new data on the Phase 1b study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia, USA.

Read more »

NanoString and Abcam Enter Commercial Partnership to Provide Expanded Menu of Antibodies for GeoMx Digital Spatial Profiler

Seattle and Cambridge, UK – NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a commercial agreement with Abcam plc (AIM:ABC), a global innovator in life science reagents and tools, for the manufacture and sale of antibodies specifically for use with NanoString’s new GeoMx™ Digital Spatial Profiler (DSP).

Read more »

Congenica Announces On-Premise Deployment Option for its SapientiaTM Platform

Cambridge, United Kingdom - Congenica, the global diagnostic decision support platform provider, has announced that it now offers an on-premise deployment method in addition to cloud deployment for running its SapientiaTM platform.

Read more »

SkinBioTherapeutics plc: CEO Designate Appointment

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX or the “Company”), a life sciences company focused on skin health, announces the appointment of Stuart Ashman as an Executive Director of the Company, subject to the completion of regulatory due diligence checks.

Read more »

Friends of Edison Spring Drinks

28 March 2019
Friends of Edison Spring Drinks
London, UK

Read more »

Labiotech - Refresh #13 in Vienna

27 March 2019
Labiotech - Refresh #13 in Vienna
Vienna, Austria

 

Read more »

Clinigen’s Foscavir® gains approval for HHV-6 encephalitis in Japan

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that Foscavir (foscarnet sodium) has received approval for the treatment of HHV-6 encephalitis from the Ministry of Health, Labour and Welfare (‘MHLW’) in Japan. Approval of the new indication by the MHLW follows reimbursement received in November 2018.

Read more »

Abcam collaborates with Visikol to develop new tools for improved tissue clearing and 3D imaging

New Jersey, USA and Cambridge, UK – Abcam, a global innovator in life science reagents and tools, and Visikol, a contract research organisation focused on advancing drug discovery, have announced a collaboration to develop new reagents and kits for improved tissue clearing and 3D imaging.

Read more »

F-star Presents New Data on its Tetravalent Bispecific Antibodies at the AACR 2019 Annual Meeting

Cambridge, UK – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel tetravalent bispecific antibodies that target the immune system to fight cancer, today announces that new preclinical data on three immuno-oncology programmes will be presented at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, US, held from 29 March – 03 April 2019.

Read more »

Downing FOUR VCT Healthcare Share Class open for tax year-end investments

London, UK – As the tax year draws to a close, the Downing FOUR Venture Capital Trust (VCT) Healthcare Share Class remains open for end of tax year investments as part of a £10.2m top-up offer.

Read more »

UK BIOTECH BOOM: 65% growth in UK biotechnology research and development companies since 2016 as sector attracts record investment

The number of active UK biotechnology businesses in the field of research and experimental development has soared by 65% in just over three years as the sector attracts record levels of funding, according to new analysis by investment manager Downing LLP.

Read more »

National Care Group expands in Gloucester by completing acquisition of Branksome House Care Services

Accrington, UK – National Care Group (“NCG”), a leading provider of support services, announces the acquisition of the business and assets of Branksome House Care Services (“Branksome”), through its subsidiary Chosen Care Limited. Financial details of the deal were not disclosed.

Read more »

Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan

Sydney, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it had received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019.

Read more »

ART MEDICAL: New Technologies Needed to Address Inadequate Implementation of Nutritional Guidelines Across the Majority of Intensive Care Units

Tel Aviv, Israel – ART MEDICAL, a medical device company that specializes in nutrition-based intensive care unit (ICU) technology, today announced the publication of an article that outlines the limitations of current ICU nutrition methods and provides insights into cutting-edge technologies that may advance this critical component of patient care into the 21st Century.  Pierre Singer, Professor of Anesthesia and Intensive Care, Sackler School of Medicine, Tel Aviv University, and ART MEDICAL CEO, Liron Elia, co-authored the article, which appears in the current issue of ICU Management & Practice Journal.

Read more »

China National Biotec Group (CNBG) and ImmunoBiology Ltd enter licensing agreement to co-develop next generation vaccine against pneumococcal disease in Greater China

Cambridge, UK - ImmunoBiology Ltd (ImmBio), a vaccine R&D company based at Babraham Research Campus near Cambridge UK, has recently signed a licensing agreement with LIBP (Lanzhou Institute of Biological Product) a subsidiary company under CNBG.

Read more »

USA Patent Granted for Recce's Antibiotics

Sydney, Australia – Recce Pharmaceuticals Ltd (ASX:RCE) (Recce or the Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced the US Patents and Trademarks Office had Granted 23 claims for patent US 10,226,482 B2, ‘Copolymer and Method for Treatment of Bacterial Infection’.

Read more »

Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced dosing of the first patient in an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

Read more »

BIA Women in Biotech Networking Evening - March

7 March 2019
BIA Women in Biotech Networking Evening - March
London, UK

Read more »

Women in Business Lunch

05 March 2019
Women in Business Lunch
London, UK

Read more »

Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, announces it has completed the first closing of its second dedicated fund focused on the microbiome, and health, nutrition and digital/connected health sectors, Health for Life Capital II™ (HFL II), with a target for the final close of over €200 million.

Read more »

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies.

Read more »

Xellia Pharmaceuticals Divests Raleigh, North Carolina Production Facilities to Sagent Pharmaceuticals

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections has entered into an agreement to divest Xellia’s Raleigh, North Carolina manufacturing plant to Sagent Pharmaceuticals Inc., (‘Sagent’), a leader of specialty pharmaceutical products with an emphasis on the injectable market.

Read more »

Seventure Partners Life Sciences Corporate Update September 2018 – February 2019

Paris, France – Seventure Partners (Seventure), one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, is pleased to provide an update on its life science investments for the period September 2018 to February 2019.
 

Read more »

Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, who will serve as Chairman of the SAB.

Read more »

Clinigen half year results - Good H1 performance with adjusted EPS up 9% and strong cash flow

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its half year results for the six months ended 31 December 2018.

Read more »

Dr. Athanasios Papadopoulos joins Emergex as Chief Medical Officer

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.

Read more »

Abcam moves to new purpose-built global headquarters

Cambridge, UK - Abcam, a global innovator in life science reagents and tools, is pleased to announce its move to new state-of-the-art global headquarters, Discovery Drive, on the Cambridge Biomedical Campus (CBC), UK, a leading hub of healthcare, science and medical research.

Read more »

Cell Medica Awarded USD 8.7 Million CPRIT Grant to Accelerate CMD-502 Off-the-shelf CAR-NKT Cell Therapy into Clinical Development

HOUSTON and LONDON – Cell Medica announced today that it has been awarded an $8.7 million research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support preclinical and clinical development of the company’s off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) therapies to treat hematological and solid tumors.

Read more »

Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

Houston, Texas and Tuebingen, Germany – Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers.

Read more »

HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has completed a $37.4 million (€33.2 million) series D financing.

Read more »

Sachs Associates 12th​ Annual European Life Sciences CEO Forum

25-26 February 2019
Sachs Associates 12th Annual European Life Sciences CEO Forum
Zurich, Switzerland

Read more »

Clinigen granted additional indication for Glycopyrronium Bromide to treat paediatric and adolescent severe hypersalivation

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA), an additional indication for Glycopyrronium Bromide 1mg/5ml Oral Solution (‘Glyco’). The new indication covers the use of Glyco in children and adolescents aged three years and older with chronic neurological disorders as symptomatic treatment of hypersalivation (severe sialorrhoea).

Read more »

Seventure Keeps up Pace of Its International Microbiome Investments, Closing Four Deals Spanning Seed to Series C

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, has closed four new investments across four countries over the past few months. The investments span the spectrum of venture investing, from seed to series C.

Read more »

Xellia Pharmaceuticals Receives US FDA Approval for Premixed Vancomycin Injection

Copenhagen, Denmark and Buffalo Grove, IL, USA - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has received U.S. Food and Drug Administration (FDA) approval for Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag in the United States market. This approval follows Qualified Infectious Disease Product (QIDP) designation from the FDA in February 2018.

Read more »

SkinBioTherapeutics plc - Issue of Equity and Related Party Transaction

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX) (“SkinBioTherapeutics” or the “Company”), a life sciences company focused on skin health, announces that it has raised a total of £1,500,000 via a placing of 9,375,000 new ordinary shares (“Placing Shares”) at a price of 16 pence per share (the “Placing”).

Read more »

Recce Successfully Raises AUD$1.8 million to Advance Lead Antibiotic Program

Sydney, Australia – Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), is pleased to announce that it has raised approximately AUD$1.8m (before costs) from sophisticated and institutional investors that will result in 12,857,143 fully paid ordinary shares being issued at AUD$0.14 per share (Placement).

Read more »

Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art research and development (R&D) facility at Milton Park, Oxfordshire.

Read more »

HOOKIPA Appoints Michael A. Kelly as Independent Director

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Michael A. Kelly to the Company’s Board of Directors.

Read more »

BIA Committee Summit 2019

14 February 2019
BIA Committee Summit 2019
London, UK

Read more »

Feedback Medical appoints radiologist and NHS England Clinical Entrepreneur Fellow as CEO

Cambridge, UK - Feedback plc (AIM: FDBK, "Feedback", or the “Company”), the specialist medical imaging technology company, announces that its operating subsidiary, Feedback Medical Ltd, has appointed Dr Tom Oakley as its Chief Executive Officer.

Read more »

SkinBioTherapeutics Half Year Results

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2018.

Read more »

OBN BioTuesday: 'What's New in Microbiome Research'

12 February 2019
OBN BioTuesday: 'What's New in Microbiome Research'
Cambridge, UK

Read more »

SAW Diagnostics Receives £1.5M Innovate UK Funding to Support Commercialisation of its Point-of-Care Diagnostics Technology Platform

Glasgow, Scotland – SAW Diagnostics Limited (SAW Dx), an emerging biological sample analysis and point-of-care diagnostic company, announced today that Innovate UK, the UK’s innovation Agency, has awarded the company a £1.5M grant in support of the company’s low-cost sample preparation system, for use in infectious disease detection and other applications.

Read more »

Biotec Pharmacon’s subsidiary, ArcticZymes launches its first ligase enzyme

Tromsø, Norway - Biotec Pharmacon's (OSE: Biotec) subsidiary ArcticZymes adds its first ligase enzyme, T4 DNA ligase, to its portfolio. T4 DNA ligase, the most widely used enzyme in the ligase family, works by joining DNA fragments together. It is used in the development of kits and products serving the In Vitro Diagnostic (IVD) and molecular research market segments.

Read more »

BioWednesday London: The J P Morgan Healthcare Conference: The Mood Music

06 February 2019
BioWednesday London: The J P Morgan Healthcare Conference: The Mood Music
Instinctif Office, London, UK

Read more »

Nick Keher appointed CFO of Clinigen Group

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Nick Keher Group Chief Financial Officer with effect from 19 March 2019. He will replace Martin Abell, who has resigned and leaves the business on 31 March 2019.

Read more »

Biotec Pharmacon awarded grant from Research Council of Norway to develop next-generation wound product

Tromsø, Norway – Biotec Pharmacon (OSE: Biotec) announces today that its subsidiary Biotec BetaGlucans has been awarded up to NOK 8 million in a grant by the Research Council of Norway for a project titled “Bioactive wound healing dressing with beta-glucan for treatment of hard-to-heal wounds”. The project is to be supported over 4 years.

Read more »

Interim update on human studies and extension of IP portfolio

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”), a life science company focused on skin health, provides interim data on the third and final phase of its human studies and an update on one of its patents.

Read more »

Biotec Pharmacon Q4 2018 Results

Biotec Pharmacon (OSE: Biotec) announces its Q4 2018 results and full year 2018 results to 31 December 2018.

Read more »

Biotec Pharmacon finalises Post Market study on Woulgan®

Tromsø, Norway – Biotec Pharmacon's (OSE: Biotec) has announced that its subsidiary, Biotec BetaGlucans, has finalised treatment in a UK Post Market Clinical Follow-up (PMCF) study on its wound care gel, Woulgan®, in diabetic foot ulcer patients.

Read more »

Abcam expands custom services capabilities with the acquisition of Calico Biolabs

Cambridge, UK - Abcam, a global innovator in life science reagents and tools, is pleased to announce its acquisition of Calico Biolabs, a developer of custom high-quality recombinant rabbit monoclonal antibodies for diagnostics and pharmaceutical company partners.

Read more »

Microbiotica Presenting at Key Microbiome Events in Q1 2019

Cambridge, UK - Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference activity for the first quarter of 2019.

Read more »

ERA Consulting: The Journey of Biopharmaceutical Innovation

25 January 2019
ERA Consulting: The Journey of Biopharmaceutical Innovation
London, UK

Read more »

BIA Gala Dinner 2019

24 January 2019
BIA Gala Dinner 2019
London, UK

Read more »

BIA Strategic Technologies in Life Sciences: The Future is now

24 January 2019
BIA Strategic Technologies in Life Sciences: The Future is now
London, UK

Read more »

Feedback plc Half Year Result

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces its unaudited half year results for the six months to 30 November 2018.

Read more »

New Combined Diagnostic and Antimicrobial Susceptibility Test Enables Resistance-Guided Therapy for Gonorrhoea

SYDNEY, AUSTRALIA and LONDON, UK – UK patients with N. gonorrhoeae (GC) now have the option of receiving the cheap and easily-administered oral antibiotic ciprofloxacin thanks to updated treatment guidelines and the availability of a novel molecular diagnostic and antimicrobial susceptibility test (AST). The new test can simultaneously diagnose gonorrhoea and provide information on whether a patient will respond to ciprofloxacin.1

Read more »

Abcam and the Loulou Foundation partner to develop key research tools for CDKL5 deficiency disorder

London and Cambridge, UK - Today, Abcam, a global innovator in life science reagents and tools, and the Loulou Foundation, a private UK-based foundation dedicated to the development of therapeutics for CDKL5 Deficiency Disorder, announced a research collaboration to discover new tools to advance research in this area of high unmet medical need.

Read more »

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform in December 2017. Further details of the milestone were not disclosed.

Read more »

Clinigen Half Year trading update

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides an unaudited trading update for the six months ended 31 December 2018.

Read more »

Clinigen extends exclusive European clinical trial sourcing and supply agreement with Accord Healthcare

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Trial Service (‘CTS’) business has extended its exclusive European clinical trial supply agreement with Accord Healthcare (‘Accord’). Clinigen is also offering pharma companies an ‘on demand’ service to Accord’s products, a first for the industry.

Read more »

Instinctif Partners’ Life Science Practice Joins New Integrated Group of Specialist Life Science Advisors, Launched at JP Morgan 2019

London, UK – The Life Science Practice of Instinctif Partners, the business communications consultancy, is pleased to announce that it has joined with other sector specialist advisors in a new integrated healthcare solution, to be formally launched by the Bridgehead Group during the annual JP Morgan conference in San Francisco from 7-9 January 2019.

Read more »

Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda) is planning to evaluate the application of recently licensed Humabodies from Crescendo for the development of novel CAR-T therapeutics.

Read more »

US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies

Munich, Germany – Immatics, a leading company in the field of cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued the 100th patent to Immatics.

Read more »

Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB’s ‘Megabody’ technology.

Read more »

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapies targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved its first research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”). The agreement, which was entered into in June 2018, grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the development of immunotherapies against hepatitis B virus (HBV) and human immunodeficiency virus (HIV).

Read more »